Montreal, Canada – February 9, 2015—Caprion announced today that its proteomics business unit, ProteoCartaTM, will be presenting data on the quantification of 190 proteins in a single assay with its new Multiple Reaction Monitoring (MRM) Assay. Data will be presented at the SLAS 4th Annual Conference being held in Washington D.C., February 7 - 11, 2015.
Caprion will also be exhibiting at Cambridge Healthtech Institute’s 22nd International Molecular Med Tri-Con 2015 conference to be held February 15 – 20, 2015 at the Moscone North Convention Center in San Francisco, CA.
SLAS Presentation:
Quantifying 190 Proteins in a Single Assay Without Antibodies Using MRM Mass Spectrometry
Wednesday, February 11th, 9:45 AM-10:15
Location: Walter E. Washington Convention Center
Presenter: Daniel Chelsky, Ph.D., Chief Scientific Officer, Caprion
This presentation will focus on a collaboration with Integrated Diagnostics that resulted in a diagnostic to distinguish between malignant and benign pulmonary nodules. The successful test, a multiplexed protein assay, was developed and launched on the MRM mass spectrometry platform. Dr. Chelsky is also chair of the Biomarker Discovery and Applications track.
“Multiplexed MRM assays offer a fast and cost-effective alternative to immunoassays for tracking panels of protein biomarkers,” stated Daniel Chelsky, Ph.D. “The ability to rapidly develop custom assays to quantify hundreds of proteins without the need for antibodies is transforming our approach to validating candidate biomarkers and drug targets as well as to better understand disease biology and drug mechanism of action.
About Caprion
Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.
Help employers find you! Check out all the jobs and post your resume.
